The availability of mTOR inhibitors for clinical treatment of TSC patients with growing angiomyolipoma, SEGA, LAM, and as adjuvant therapy for refractory epilepsy positively impacts the clinical outcome and highlights the need for early diagnosis of the disease [2]. Here, MTOR is linked to epilepsy.